NCT02304315View on ClinicalTrials.gov

A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Hepatitis B Infection
Interventions
BIOLOGICAL

GC1102 50,000 IU

a recombinant hepatitis B immunoglobulin

BIOLOGICAL

GC1102 80,000 IU

a recombinant hepatitis B immunoglobulin

Trial Locations (1)

Unknown

Seoul Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY